<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2014.3220</article-id>
<article-id pub-id-type="publisher-id">or-32-02-0559</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal-epithelial reverting transition</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>JIANG</surname><given-names>HANGUO</given-names></name><xref ref-type="corresp" rid="c1-or-32-02-0559"/></contrib>
<contrib contrib-type="author">
<name><surname>GAO</surname><given-names>MEI</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>SHEN</surname><given-names>ZHIHUA</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>LUO</surname><given-names>BOTAO</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>RUJIA</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>JIANG</surname><given-names>XIAOFAN</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>DING</surname><given-names>RANRAN</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>HA</surname><given-names>YANPING</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>ZHENLIANG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>JIE</surname><given-names>WEI</given-names></name><xref ref-type="corresp" rid="c1-or-32-02-0559"/></contrib>
<aff id="af1-or-32-02-0559">Department of Pathology, School of Basic Medicine Science, Guangdong Medical College, Zhanjiang, Guangdong 524023, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-or-32-02-0559">Correspondence to: Dr Hanguo Jiang or Dr Wei Jie, Department of Pathology, School of Basic Medicine Science, Guangdong Medical College, Zhanjiang, Guangdong 524023, P.R. China, E-mail: <email>jianghg12@163.com</email>, E-mail: <email>jiewei74@126.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>05</month>
<year>2014</year></pub-date>
<volume>32</volume>
<issue>2</issue>
<fpage>559</fpage>
<lpage>566</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>02</month>
<year>2014</year></date>
<date date-type="accepted">
<day>09</day>
<month>04</month>
<year>2014</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>In the present study, we evaluated the role of phosphatidylinositol-3 OH kinase/protein kinase B (PI3K/Akt) signaling on changes to epithelial-to-mesenchymal reverting transition (EMrT) in nasopharyngeal carcinoma (NPC). Protein expression levels of p-Akt (Ser473), and the epithelial-to-mesenchymal transition (EMT) markers E-cadherin, vimentin, &#x003B1; smooth muscle actin (&#x003B1;-SMA), were examined in clinical samples from 130 cases of undifferentiated non-keratinizing NPC, and 20 cases of benign nasopharyngitis. The relationship between protein expression levels and the statue of NPC lymph node metastasis was analyzed. The poorly-differentiated NPC cell line CNE2Z was treated with various concentrations of the PI3K inhibitor, LY294002, and western blotting and quantitative polymerase chain reaction assays were used to analyze the activation of PI3K/Akt signaling and expression of E-cadherin, vimentin and &#x003B1;-SMA. The ability of cellular migration and invasion was assessed using Transwell assays. The <italic>in vivo</italic> effects of LY294002 on metastasis and expression of EMT markers in CNE2Z cells was evaluated using tumor xenograft experiments. The expression levels of p-Akt (Ser473) in NPC samples were higher than those in nasopharyngitis. There were reduced levels of membrane E-cadherin protein expression, and increased cytosol vimentin and &#x003B1;-SMA expression levels in NPC samples compared with those in nasopharyngitis samples. High expression levels of p-Akt (Ser473), vimentin, and &#x003B1;-SMA, and low expression levels of E-cadherin were positively associated with lymph node metastasis of NPC cells. Treating CNE2Z cells with LY294002 inhibited p-Akt (Ser473), vimentin and &#x003B1;-SMA expression but upregulated E-cadherin expression, leading to significantly attenuated cell invasion and migration. Administration of mice with LY294002 resulted in upregulation of membrane E-cadherin, and downregulation of vimentin and &#x003B1;-SMA in CNE2Z xenografts, with reduced pulmonary metastasis. Our findings suggest that inhibiting the PI3K/Akt pathway using LY294002 attenuated NPC metastasis via induction of EMrT.</p></abstract>
<kwd-group>
<kwd>nasopharyngeal carcinoma</kwd>
<kwd>PI3K/Akt signaling</kwd>
<kwd>mesenchymal-epithelial transition</kwd>
<kwd>mesenchymal-epithelial reverting transition</kwd>
<kwd>LY294002</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Nasopharyngeal carcinoma (NPC) is one of the most common carcinomas in Southern China, particularly in Guangdong Province; however, it is rare in most other regions of the world (<xref rid="b1-or-32-02-0559" ref-type="bibr">1</xref>,<xref rid="b2-or-32-02-0559" ref-type="bibr">2</xref>). NPC cells are highly malignant, often invading adjacent regions and metastasizing to regional lymph nodes and distant organs. Despite radiation therapy or adjunctive chemotherapy, 30&#x02013;40&#x00025; of NPC patients die from local recurrence and distant metastasis (<xref rid="b3-or-32-02-0559" ref-type="bibr">3</xref>). A better understanding of the molecular mechanisms contributing to NPC progression may provide new insights into possible therapeutic targets.</p>
<p>Increasing evidence indicates that metastasis of many epithelium-derived tumors is closely correlated with epithelial-to-mesenchymal transition (EMT) (<xref rid="b4-or-32-02-0559" ref-type="bibr">4</xref>&#x02013;<xref rid="b7-or-32-02-0559" ref-type="bibr">7</xref>). EMT is characterized by cells losing their epithelial morphology, and acquiring fibroblast-like properties. They also exhibit reduced intercellular adhesion and increased motility (<xref rid="b8-or-32-02-0559" ref-type="bibr">8</xref>). Loss of E-cadherin expression and increased expression levels of mesenchymal cell markers such as vimentin, N-cadherin, fibronectin and &#x003B1; smooth muscle actin (&#x003B1;-SMA) appear to be strongly correlated with EMT. Suppression of E-cadherin by transcriptional regulators such as Snail or Twist has emerged as a critical step driving EMT (<xref rid="b9-or-32-02-0559" ref-type="bibr">9</xref>). Previously, it was reported that cancer cells could acquire epithelial-to-mesenchymal reverting transition (EMrT) to adapt to metastatic microenvironments, with re-expression of E-cadherin, an indicator of EMrT (<xref rid="b10-or-32-02-0559" ref-type="bibr">10</xref>,<xref rid="b11-or-32-02-0559" ref-type="bibr">11</xref>). Under such conditions, cancer cells continue to display phenotypic plasticity beyond the EMT that initiates metastasis. To date, little is known about the precise mechanisms, biology, and clinical significance of EMrT in NPC.</p>
<p>Previous studies revealed that several signaling pathways are involved in EMT and EMrT (<xref rid="b9-or-32-02-0559" ref-type="bibr">9</xref>,<xref rid="b12-or-32-02-0559" ref-type="bibr">12</xref>,<xref rid="b13-or-32-02-0559" ref-type="bibr">13</xref>). The phosphatidylinositol-3 OH kinase/protein kinase B (PI3K/Akt) signaling pathway is constitutively activated in various epithelial cancers, and plays an important role in tumor formation and metastasis (<xref rid="b14-or-32-02-0559" ref-type="bibr">14</xref>,<xref rid="b15-or-32-02-0559" ref-type="bibr">15</xref>). Phosphatidylinositol 3,4,5-triphosphate (PIP3), generated from PI3K, acts as a lipid second messenger essential for the translocation of Akt to the plasma membrane. Akt is phosphorylated at two sites, T308 in the kinase domain and S473 in the regulatory tail. Phosphorylation at T308 and S473 is essential for maximal Akt activation. Phosphorylated Akt (p-Akt) regulates the function of a broad array of intracellular proteins involved in fundamental processes, including cell proliferation, cell death, cell motility/adhesion, cell transformation, neovascularization and the inhibition of apoptosis. It has been reported that Akt suppresses transcription of the E-cadherin gene (<xref rid="b10-or-32-02-0559" ref-type="bibr">10</xref>,<xref rid="b16-or-32-02-0559" ref-type="bibr">16</xref>). This transcriptional suppression induces responses leading to the conversion of epithelial cells into invasive mesenchymal cells.</p>
<p>A chemical inhibitor of PI3K, 2&#x02013;4-morpholinyl-8-phenylchromone (LY294002), has been extensively used to study the role of the PI3K/AKT pathway in normal and transformed cells. Inactivation of PI3K using LY294002 has been shown to lead to the dephosphorylation of Akt at T308 and S473. A consequence of this is induction of G1 arrest during cell growth, which leads to apoptosis. Inhibitors of PI3K also possess antitumor activity <italic>in vitro</italic> and <italic>in vivo</italic> in a variety of tumors. It is possible that cells constitutively expressing active Akt become dependent on its ability to promote survival. Although these results have been observed in many human cancers, the effects of LY294002 on EMrT and metastasis in human NPC remain unclear. In the present study, we investigated the role of PI3K/Akt signaling activation and inhibition in EMrT for human NPC cases.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title>Sample collection and ethics</title>
<p>Human benign nasopharyngeal samples (chronic nasopharyngitis, n=20) and NPC samples (n=130) were obtained from the Affiliated Gaozhou Hospital, and the Affiliated Hospital of Guangdong Medical College. All NPC patients were diagnosed with non-keratinizing carcinoma following histological examination. Tissues were paraffin-embedded and sectioned (4-&#x003BC;m thickness). Of the 130 NPC cases, 53 involved local lymph node metastasis; of these 53 cases, 23 were paired with primary and metastatic lesions. The use of human tissues in this study was approved by the Ethics Council of the Affiliated Gaozhou Hospital, and the Affiliated Hospital of Guangdong Medical College.</p></sec>
<sec>
<title>Immunohistochemistry (IHC)</title>
<p>Paraffin-embedded sections were used for immunohistochemical analysis of p-Akt (Ser473), E-cadherin, vimentin and &#x003B1;-SMA expression. Sections were deparaffinized and rehydrated, then heat-induced antigen retrieval at 95&#x000B0;C was conducted in sodium citrate buffer (10 mM, pH 6.0). Endogenous peroxidases were blocked using 0.3&#x00025; (v/v) H<sub>2</sub>O<sub>2</sub>, while binding of non-specific proteins was blocked with 10&#x00025; goat serum. Sections were then incubated with primary antibodies against p-Akt (Ser473) (1/200 dilution; Cell Signaling, Danvers, MA, USA), E-cadherin (1/200) and vimentin (1/200) (both from Cell Signaling), and &#x003B1;-SMA (1/100; Maixin Bio, Fujiang, China) at 4&#x000B0;C overnight. Non-immune immunoglobulin G (IgG) was used as a negative control. Antigenic sites were visualized using a streptavidin-peroxidase (SP) and a 3,3&#x02032;-diaminobenzidine (DAB) kit (ZSGB-BIO, Beijing, China). Expression of p-Akt (Ser473), vimentin, and &#x003B1;-SMA was localized to the cytoplasm, while E-cadherin signals were observed in the cell membrane or cytoplasm. Scoring of sections was conducted by two experienced pathologists, blinded to the identity of samples. Staining intensity was classified as 0 (negative); 1 (weak); 2 (moderate); and 3 (strong). The proportion of p-Akt (Ser473)-, E-cadherin-, vimentin- and &#x003B1;-SMA-positive cells was scored as 1 (0&#x02013;9&#x00025; positive); 2 (10&#x02013;50&#x00025;); and 3 (&gt;50&#x00025;). Samples with a sum immunoreactive score (IRS) &#x02265;1 were considered to be positive for p-Akt (Ser473), E-cadherin, vimentin and &#x003B1;-SMA.</p></sec>
<sec>
<title>Cell culture</title>
<p>The poorly differentiated human NPC cell line, CNE2Z, was maintained as described previously (<xref rid="b17-or-32-02-0559" ref-type="bibr">17</xref>&#x02013;<xref rid="b19-or-32-02-0559" ref-type="bibr">19</xref>). Briefly, CNE2Z cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Life Technologies, Guangzhou, China) supplemented with 10&#x00025; fetal bovine serum (FBS; Gibco), 100 U/ml penicillin and 100 &#x003BC;g/ml streptomycin at 37&#x000B0;C/5&#x00025; CO<sub>2</sub>. LY294002 (Cayman Chemical Co., Ann Arbor, MI, USA) was dissolved in dimethyl sulfoxide (DMSO), and the final concentration of DMSO in growth medium was 0.5&#x00025; (v/v). CNE2Z cells were incubated in DMEM containing 0.5&#x00025; FBS for 24 h; media were then replaced with complete growth medium containing LY294002 at 10, 25, 50 or 75 &#x003BC;M, or DMSO (0.5&#x00025;, v/v) for 48 h; cells were then harvested for use in relevant experiments.</p></sec>
<sec>
<title>In vitro cell invasion and migration assays</title>
<p>Cell invasion assays were conducted using Transwell chambers containing membranes with 8 &#x003BC;m pores. The upper surfaces of the Transwell chambers were coated with Matrigel matrix (250 &#x003BC;l/ml) overnight at 4&#x000B0;C, then rehydrated with 0.1&#x00025; (w/v) bovine serum albumin (BSA) in DMEM for 1 h at 37&#x000B0;C. Transwell chambers were then placed into 24-well culture plates. CNE2Z cells (5&#x000D7;10<sup>5</sup>) were suspended in 200 &#x003BC;l of complete growth media supplemented with LY294002 (10, 25, 50 or 75 &#x003BC;M), or DMSO (0.5&#x00025;, v/v), and were then added to the upper chambers and allowed to migrate toward the underside of the membrane. Membranes were fixed with 3.5&#x00025; paraformaldehyde 24 h later; cells on the upper surface of the membrane were removed by wiping with a cotton swab, and then membranes were mounted onto glass slides. Cells on the lower faces of the membranes were counted, with 20 random fields of view per membrane counted for each assay. For cell migration assays, the protocol was similar to that used in cell invasion assays, except that Matrigel was not added to the upper chambers.</p></sec>
<sec>
<title>Quantitative polymerase chain reaction (qPCR) assays</title>
<p>The CNE2Z cells were treated with LY294002 (10, 25, 50 and 75 &#x003BC;M) and DMSO (0.5&#x00025;, v/v) for 24 h. Total RNA was extracted using Takara RNAiso Plus reagent (Takara Biotechnology Co., Ltd., China). We used the Promega RT System and oligo(dT)18, along with total RNA (1 &#x003BC;g) as a template to generate first strand cDNA. Specific primer pairs for the amplification of E-cadherin (5&#x02032;-TTG CTA CTG GAA CAG GGA CAC-3&#x02032; and 5&#x02032;-CCC GTG TGT TAG TTC TGC TGT-3&#x02032;), vimentin (5&#x02032;-TGC GTG AAA TGG AAG AGA ACT-3&#x02032; and 5&#x02032;-TCA GGT TCA GGG AGG AAA AGT-3&#x02032;), &#x003B1;-SMA (5&#x02032;-TCC CTT GAG AAG AGT TAC GAG TTG-3&#x02032; and 5&#x02032;-ATG ATG CTG TTG TAG GTG GTT TC-3&#x02032;), and &#x003B2;-actin (5&#x02032;-TGA CGT GGA CAT CCG CAA AG-3&#x02032; and 5&#x02032;-CTG GAA GGT GGA CAG CGA GG-3&#x02032;) were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The total reaction (20 &#x003BC;l) comprised 10 &#x003BC;l of SYBR-Green I PCR Master Mix (Roche), 0.8 &#x003BC;l of each primer (10 &#x003BC;M), 2 &#x003BC;l of cDNA and 6.4 &#x003BC;l of double-distilled water. Thermal cycling involved an initial denaturation step at 95&#x000B0;C for 5 min, followed by 45 cycles at 95&#x000B0;C for 25 sec, and 60&#x000B0;C for 60 sec, in a LightCycler 480 II instrument (Roche China Ltd., Shanghai, China). The relative abundances of target mRNAs were determined from Ct values and plotted as fold-change compared with the control group. The transcription levels of &#x003B2;-actin served as a loading control.</p></sec>
<sec>
<title>Western blot analysis</title>
<p>Cells were homogenized with lysis buffer (1&#x00025; Triton X-100, 50 mM Tris-HCl pH 7.5, 0.1&#x00025; SDS, 150 mM NaCl, 10&#x00025; glycerol, 1.5 mM MgCl<sub>2</sub>, 1 mM PMSF, 0.1 mM NaV0<sub>4</sub>, 0.1 mM benzamidine, 5 &#x003BC;l/ml leupeptin and 5 &#x003BC;l/ml aprotinin), and protein homogenates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to nitrocellulose membranes. Membranes were incubated with primary antibodies against p-Akt (Ser473) (1:1,000 dilution), E-cadherin (1:500), vimentin (1:500) (all from Cell Signaling), &#x003B1;-SMA (1:500; Maxin Bio), and &#x003B2;-actin (1:1000; Santa Cruz, Dallas, TX, USA) at 4&#x000B0;C overnight. Membranes were washed twice and incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature. Protein bands were visualized using enhanced chemiluminescent reagents (Thermo Fisher, Rockford, IL, USA) and analyzed using an InGenius LHR Gel Documentation System (Syngene, Frederick, MD, USA).</p></sec>
<sec>
<title>Tumor xenograft experiments</title>
<p>Specific pathogen-free (SPF) Balb/c null mice (6&#x02013;8 weeks old) were purchased from the Experimental Animal Center of Guangdong Medical College. Mice were housed in a facility with controlled temperature, humidity, and a 12 h light/dark cycle. All animal procedures were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Medical College. CNE2Z cells (1&#x000D7;10<sup>6</sup> cells/mouse) were subcutaneously injected (200 &#x003BC;l) into the right flanks of mice. After 1 week, tumor-bearing mice were intraperitoneally injected twice a week with 0.5&#x00025; DMSO (n=4) or LY294002 (10, 25, 50 or 75 mg/kg; n=4 for each group) for 4 weeks. Mice were monitored, with body weight and tumor sizes measured twice a week. All mice were euthanized at the end of the treatment period. Portions of the xenografts were fixed in natural formalin, and embedded in paraffin for immunohistochemical analysis of EMT markers. Xenografts that were not fixed were stored at &#x02212;80&#x000B0;C. Lungs of each mouse were collected, the intermittent sections (10 sections/lung, 20 sections/mouse) were stained with H&amp;E and the tumor metastatic lesions were calculated.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Statistical analyses were conducted using GraphPad Prism (GraphPad Software, CA, USA). We used &#x003C7;<sup>2</sup> tests to analyze and compare expression of p-Akt (Ser473) and EMT markers in clinical samples. Data for <italic>in vitro</italic> experiments are expressed as the means &#x000B1; SD. Differences between two groups were analyzed using Student&#x02019;s t-test. For comparison of multiple groups, ANOVAs were used followed by the Student-Newman-Keuls test. P-values &lt;0.05 were considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Activation of PI3K/Akt signaling and expression of EMT markers in NPC</title>
<p>Positive expression of p-Akt (Ser473) in chronic nasopharyngitis and NPC samples was observed in 25&#x00025; (5/20) and 76.2&#x00025; (99/130) of samples, respectively (P&lt;0.001) (<xref rid="tI-or-32-02-0559" ref-type="table">Table I</xref>, <xref rid="f1-or-32-02-0559" ref-type="fig">Fig. 1</xref>), indicating the activation of PI3K/Akt signaling in NPCs. Expression levels of membrane E-cadherin, cytosol vimentin and &#x003B1;-SMA proteins in chronic nasopharyngitis samples were 100&#x00025; (20/20), 0&#x00025; and 0&#x00025;, respectively. For NPC samples, expression levels of these proteins were 75&#x00025; (98/130), 41&#x00025; (53/130) and 37&#x00025; (48/130) (P&lt;0.05, 0.001 and 0.01, respectively). Spindle and fibroblast-like tumor cells in NPC samples exhibited intense vimentin and &#x003B1;-SMA staining. These results indicated that, when compared with the benign chronic nasopharyngitis, the NPCs presented a much stronger activation of PI3K/Akt signaling, obvious downregulation in membrane E-cadherin and upregulation in cytosol vimentin and &#x003B1;-SMA protein expressions.</p></sec>
<sec>
<title>Activation of PI3K/Akt signaling and EMT contribute to clinical NPC metastasis</title>
<p>Of the 130 NPC samples, 53 cases had signs of cervical lymph node metastasis. High levels of p-Akt (Ser473) expression were observed in cases with local lymph node metastasis compared with those without metastasis &#x0005B;89&#x00025; (47/53) vs. 68&#x00025; (52/77), P&lt;0.01&#x0005D;. Expression levels of membrane E-cadherin, cytosol vimentin and &#x003B1;-SMA in NPC samples with local lymph node metastasis were 62&#x00025; (33/53), 60&#x00025; (32/53) and 47&#x00025; (25/53), and 84&#x00025; (65/77), 27&#x00025; (21/77) and 30&#x00025; (23/77) in samples without local lymph node metastasis (P&lt;0.01, 0.001 and 0.05, respectively). To further investigate the role of PI3K/Akt activation and EMT occurrence in NPC metastasis, we analyzed the expression of p-Akt (Ser473) and EMT genes in NPC samples matched with primary and secondary lesions (n=23). Although expression of &#x003B1;-SMA was not significantly different between primary and metastatic lesions, higher p-Akt (Ser473) and vimentin expression levels, and lower membrane E-cadherin expression levels, were observed in secondary NPC metastatic lesions (P&lt;0.05) (<xref rid="tI-or-32-02-0559" ref-type="table">Table I</xref>).</p></sec>
<sec>
<title>Inhibition of PI3K/Akt signaling alters expression of p-Akt (Ser473) and EMT marker genes in CNE2Z cells in vitro</title>
<p>Treatment of CNE2Z cells with LY294002 significantly suppressed p-Akt (Ser473) expression in a concentration-dependent manner; particularly at 75 &#x003BC;M, the expression of p-Akt (Ser473) was almost completely attenuated (<xref rid="f2-or-32-02-0559" ref-type="fig">Fig. 2A</xref>). Treatment of CNE2Z cells with LY294002 led to upregulation of E-cadherin and downregulation of vimentin and &#x003B1;-SMA at the protein and mRNA levels (<xref rid="f2-or-32-02-0559" ref-type="fig">Fig. 2B and C</xref>), and to EMrT <italic>in vitro</italic>.</p></sec>
<sec>
<title>Inhibition of PI3K/Akt signaling attenuates invasion and migration in CNE2Z cells in vitro</title>
<p>The ability of cellular migration and invasion was used to assess functional changes <italic>in vitro</italic> following inhibition of PI3K/Akt signaling. As we expected, LY294002 treatment of CNE2Z cells indeed significantly suppressed cell migration and invasion in a concentration-dependent manner (<xref rid="f3-or-32-02-0559" ref-type="fig">Fig. 3</xref>).</p></sec>
<sec>
<title>Effects of LY294002 on the expression of EMT marker genes in vivo</title>
<p>Western blot results revealed that xenografts from mice administered with DMSO displayed low levels of E-cadherin expression and high levels of vimentin and &#x003B1;-SMA expression. Mice treated with LY294002 had increased levels of E-cadherin, and decreased levels of vimentin and &#x003B1;-SMA that were dependent on the concentration of LY294002 (<xref rid="f4-or-32-02-0559" ref-type="fig">Fig. 4</xref>). Consistent with the western blot results, the IHC results exhibited the same tendencies (<xref rid="f5-or-32-02-0559" ref-type="fig">Fig. 5</xref>), and these results were consistent with those found <italic>in vitro</italic> (<xref rid="f2-or-32-02-0559" ref-type="fig">Fig. 2</xref>).</p></sec>
<sec>
<title>Effects of LY294002 on NPC cells in pulmonary metastasis in vivo</title>
<p>After all mice were euthanized, metastatic lesions in organs such as the liver, spleen, lung and brain were examined. At the gross level, metastatic lesions were not found in the liver, spleen, lung and brain of any mice. At the microscopic level, pulmonary metastatic lesions were observed in each group, with the following mean total number of pulmonary metastatic lesions: 23.25, 11.25, 3.75, 0 and 0, respectively (P&lt;0.001, <xref rid="f6-or-32-02-0559" ref-type="fig">Fig. 6</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The PI3K/Akt cascade is known to be an important signal transduction pathway involved in cell survival and apoptosis. This pathway is activated by other factors that play a critical role in regulating tumor cell growth, survival, differentiation, motility and invasion (<xref rid="b14-or-32-02-0559" ref-type="bibr">14</xref>). We have previously shown that inhibition of PI3K/Akt signaling using LY294002 inhibits CNE2Z cell proliferation, and induces apoptosis <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="b20-or-32-02-0559" ref-type="bibr">20</xref>). As a hallmark of malignant cancers, invasion and metastasis are major features that contribute to cancerous progression (<xref rid="b21-or-32-02-0559" ref-type="bibr">21</xref>). Previous findings have indicated that metastasis of many epithelium-derived tumors have a close correlation with EMT. During EMT, epithelial cell-derived tumor cells acquire fibroblast-like properties. Loss of the E-cadherin protein is a key molecular event during EMT (<xref rid="b10-or-32-02-0559" ref-type="bibr">10</xref>,<xref rid="b22-or-32-02-0559" ref-type="bibr">22</xref>).</p>
<p>In the present study, we examined the expression of p-Akt (Ser473) and EMT markers in chronic nasopharyngitis and NPC tissues. Our findings indicated that higher levels of p-Akt (Ser473), vimentin and &#x003B1;-SMA expression, and lower membrane E-cadherin expression levels were observed in clinical NPC samples, indicating that activation of PI3K/Akt signaling and the occurrence of EMT was associated with NPC pathogenesis. We then assessed the relationship between changes in p-Akt (Ser473) and EMT marker expression levels to NPC metastasis. Consistent with our expectations, activation of PI3K/Akt signaling and occurrence of EMT were associated with NPC metastasis. Results from the 23 cases of NPC patients matched with primary and secondary lesions further highlighted this relationship. We observed expression of E-cadherin in the membranes of benign nasopharyngeal epithelia, while decreased levels of membrane expression and increased cytoplasmic E-cadherin expression were apparent in NPC tumor cells. Vimentin and &#x003B1;-SMA expression was lacking in benign nasopharyngeal epithelial cells, except for some stromal cells. Certain NPC cells, particularly spindle and fibroblast-like tumor cells, displayed increased levels of vimentin and &#x003B1;-SMA expression; however, these were reduced in adjacent epithelial-like cancer cells. Our results confirmed that EMT was detected in clinical NPC samples. The occurrence of EMT has a close relationship with metastasis of NPC cells, as detailed in other reports (<xref rid="b23-or-32-02-0559" ref-type="bibr">23</xref>&#x02013;<xref rid="b25-or-32-02-0559" ref-type="bibr">25</xref>).</p>
<p>Treatment of the CEN2Z cell line with LY294002 significantly attenuated the levels of p-Akt(ser473)/Akt in a concentration-dependent manner, indicating a suppression of PI3K/Akt signaling in these cells. Increased levels of E-cadherin, and lower levels of vimentin and &#x003B1;-SMA expression, were observed. Consistent with our expectations, these molecular changes in LY294002-treated CNE2Z cells resulted in reduced migration and invasion of cells. Our findings <italic>in vitro</italic> showed that inhibition of PI3K/Akt signaling led to EMrT in NPC cells. Our results are supported by those from other research groups, which showed that inhibition of Akt led to upregulation of E-cadherin in lung (<xref rid="b26-or-32-02-0559" ref-type="bibr">26</xref>) and gastric cancer (<xref rid="b27-or-32-02-0559" ref-type="bibr">27</xref>) cells.</p>
<p>The microenvironment of cancer cells is very complex and flexible. Epithelial cell-derived cancer cells acquire features of stromal cells and re-express E-cadherin to adapt to their new environment for certain stimuli. This leads to EMrT and abrogated cell motility (<xref rid="b6-or-32-02-0559" ref-type="bibr">6</xref>,<xref rid="b28-or-32-02-0559" ref-type="bibr">28</xref>). To assess the effects of LY294002 on NPC cell metastasis <italic>in vivo</italic>, CNE2Z xenograft experiments were conducted. After tumor-bearing Balb/c null mice were administered LY294002 at various concentrations, primary tumor masses were analyzed for activation of Akt and expression of EMT markers. We observed attenuated Akt activation, which was accompanied by upregulation of E-cadherin and downregulation of vimentin and &#x003B1;-SMA. Thus, LY294002 administration <italic>in vivo</italic> effectively leads to EMrT. Consistent with changes in EMT markers in xenografts, significantly reduced pulmonary metastasis was also observed. Therefore, we concluded that LY294002 administration <italic>in vivo</italic> inhibits tumor cell metastasis via EMrT, which was mediated by the suppression of PI3K/Akt signaling.</p>
<p>It has been reported that EMT of many epithelium-derived tumors is regulated by multiple signal transduction pathways that form complex networks (<xref rid="b29-or-32-02-0559" ref-type="bibr">29</xref>). Our findings suggest that Akt kinase was one of the major effectors of EMT signals downstream of PI3K in NPC cells. Previous studies have demonstrated that EMT generates cells with the properties of stem cells (<xref rid="b30-or-32-02-0559" ref-type="bibr">30</xref>). Recent reports also indicate that EMT occurs in NPC cells due to the existence of stem cell-like cancerous cells (<xref rid="b31-or-32-02-0559" ref-type="bibr">31</xref>&#x02013;<xref rid="b33-or-32-02-0559" ref-type="bibr">33</xref>). Future studies should focus on investigating the contribution of Akt mediation to the biology of cancer stem cell-like cells in NPC.</p>
<p>There were some limitations to the present study; upstream PI3K/Akt signaling and inhibition of PI3K/Akt signaling besides using LY294002 in NPC should be considered, and the number of cases within animal experiments should be greater. Considering that activation of PI3K/Akt signaling crosstalks with other cascades (<xref rid="b34-or-32-02-0559" ref-type="bibr">34</xref>), the present investigation outlined the clinical significance of LY294002 in the treatment of NPC.</p>
<p>In conclusion, we showed that EMT characteristics were apparent in NPC tissues, and that administration of LY294002 in CNE2Z cells induced upregulation of E-cadherin and downregulation of &#x003B1;-SMA and vimentin <italic>in vitro</italic> and <italic>in vivo</italic>. This led to impaired cell metastasis <italic>via</italic> the induction of EMrT. Our results highlight the possibility of targeting the PI3K/Akt pathway as a therapeutic strategy for controlling NPC cell invasion and metastasis. We consider that this concept for NPC may then be applied to other carcinomas.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by grants from the Research Program of Guangdong Medical College (B2011018, B2010013 and Z2013004), and the Guangdong Provincial Medical Research Foundation (A2013421).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-32-02-0559"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>SM</given-names></name><name><surname>Simons</surname><given-names>MJ</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name></person-group><article-title>The prevalence and prevention of nasopharyngeal carcinoma in China</article-title><source>Chin J Cancer</source><volume>30</volume><fpage>114</fpage><lpage>119</lpage><year>2011</year></element-citation></ref>
<ref id="b2-or-32-02-0559"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>ET</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name></person-group><article-title>The enigmatic epidemiology of nasopharyngeal carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>15</volume><fpage>1765</fpage><lpage>1777</lpage><year>2006</year></element-citation></ref>
<ref id="b3-or-32-02-0559"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>ZA</given-names></name><name><surname>Pan</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy</article-title><source>Ai Zheng</source><volume>28</volume><fpage>1143</fpage><lpage>1148</lpage><year>2009</year><comment>(In Chinese)</comment></element-citation></ref>
<ref id="b4-or-32-02-0559"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name></person-group><article-title>New insights of epithelial-mesenchymal transition in cancer metastasis</article-title><source>Acta Biochim Biophys Sin</source><volume>40</volume><fpage>643</fpage><lpage>650</lpage><year>2008</year></element-citation></ref>
<ref id="b5-or-32-02-0559"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Dedhar</surname><given-names>S</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>EW</given-names></name></person-group><article-title>The epithelial-mesenchymal transition: new insights in signaling, development, and disease</article-title><source>J Cell Biol</source><volume>172</volume><fpage>973</fpage><lpage>981</lpage><year>2006</year></element-citation></ref>
<ref id="b6-or-32-02-0559"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Vahdat</surname><given-names>LT</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Mittal</surname><given-names>V</given-names></name></person-group><article-title>Microenvironmental regulation of epithelial-mesenchymal transitions in cancer</article-title><source>Cancer Res</source><volume>72</volume><fpage>4883</fpage><lpage>4889</lpage><year>2012</year></element-citation></ref>
<ref id="b7-or-32-02-0559"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>LJ</given-names></name><name><surname>Bhattacharya</surname><given-names>SD</given-names></name><name><surname>Kuo</surname><given-names>PC</given-names></name></person-group><article-title>Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies</article-title><source>Int J Biochem Mol Biol</source><volume>3</volume><fpage>117</fpage><lpage>136</lpage><year>2012</year></element-citation></ref>
<ref id="b8-or-32-02-0559"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group><article-title>Epithelial-mesenchymal transitions in tumour progression</article-title><source>Nat Rev Cancer</source><volume>2</volume><fpage>442</fpage><lpage>454</lpage><year>2002</year></element-citation></ref>
<ref id="b9-or-32-02-0559"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>MA</given-names></name><name><surname>Kraut</surname><given-names>N</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name></person-group><article-title>Molecular requirements for epithelial-mesenchymal transition during tumor progression</article-title><source>Curr Opin Cell Biol</source><volume>17</volume><fpage>548</fpage><lpage>558</lpage><year>2005</year></element-citation></ref>
<ref id="b10-or-32-02-0559"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>A</given-names></name><name><surname>Yates</surname><given-names>C</given-names></name><name><surname>Shepard</surname><given-names>CR</given-names></name></person-group><article-title>E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas</article-title><source>Clin Exp Metastasis</source><volume>25</volume><fpage>621</fpage><lpage>628</lpage><year>2008</year></element-citation></ref>
<ref id="b11-or-32-02-0559"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>YL</given-names></name><name><surname>Shepard</surname><given-names>CR</given-names></name><name><surname>Wells</surname><given-names>A</given-names></name></person-group><article-title>Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition</article-title><source>Mol Cancer</source><volume>9</volume><fpage>179</fpage><year>2010</year></element-citation></ref>
<ref id="b12-or-32-02-0559"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name></person-group><article-title>Multilayer control of the EMT master regulators</article-title><source>Oncogene</source><volume>33</volume><fpage>1755</fpage><lpage>1763</lpage><year>2014</year></element-citation></ref>
<ref id="b13-or-32-02-0559"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Han</surname><given-names>HJ</given-names></name></person-group><article-title>Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3&#x003B2;, Snail1, and &#x003B2;-catenin in renal proximal tubule cells</article-title><source>Am J Physiol Renal Physiol</source><volume>298</volume><fpage>F1263</fpage><lpage>F1275</lpage><year>2010</year></element-citation></ref>
<ref id="b14-or-32-02-0559"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KM</given-names></name><name><surname>Anderson</surname><given-names>NG</given-names></name></person-group><article-title>The protein kinase B/Akt signalling pathway in human malignancy</article-title><source>Cell Signal</source><volume>14</volume><fpage>381</fpage><lpage>395</lpage><year>2002</year></element-citation></ref>
<ref id="b15-or-32-02-0559"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>M</given-names></name><name><surname>Pardee</surname><given-names>AB</given-names></name></person-group><article-title>Metastasis and AKT activation</article-title><source>J Cell Physiol</source><volume>218</volume><fpage>451</fpage><lpage>454</lpage><year>2009</year></element-citation></ref>
<ref id="b16-or-32-02-0559"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grille</surname><given-names>SJ</given-names></name><name><surname>Bellacosa</surname><given-names>A</given-names></name><name><surname>Upson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines</article-title><source>Cancer Res</source><volume>63</volume><fpage>2172</fpage><lpage>2178</lpage><year>2003</year></element-citation></ref>
<ref id="b17-or-32-02-0559"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression</article-title><source>J Transl Med</source><volume>11</volume><fpage>217</fpage><year>2013</year></element-citation></ref>
<ref id="b18-or-32-02-0559"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><etal/></person-group><article-title>High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression</article-title><source>BMC Cancer</source><volume>13</volume><fpage>192</fpage><year>2013</year></element-citation></ref>
<ref id="b19-or-32-02-0559"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jie</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>QY</given-names></name><name><surname>Luo</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Inhibition of Pim-1 attenuates the proliferation and migration in nasopharyngeal carcinoma cells</article-title><source>Asian Pac J Trop Med</source><volume>5</volume><fpage>645</fpage><lpage>650</lpage><year>2012</year></element-citation></ref>
<ref id="b20-or-32-02-0559"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name></person-group><article-title>Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo</article-title><source>J Exp Clin Cancer Res</source><volume>29</volume><fpage>34</fpage><year>2010</year></element-citation></ref>
<ref id="b21-or-32-02-0559"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><year>2011</year></element-citation></ref>
<ref id="b22-or-32-02-0559"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>KO</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells</article-title><source>J Exp Clin Cancer Res</source><volume>28</volume><fpage>28</fpage><year>2009</year></element-citation></ref>
<ref id="b23-or-32-02-0559"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>WR</given-names></name><name><surname>Chen</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Wu</surname><given-names>AB</given-names></name><name><surname>Yao</surname><given-names>KT</given-names></name></person-group><article-title>Neoplastic spindle cells in nasopharyngeal carcinoma show features of epithelial-mesenchymal transition</article-title><source>Histopathology</source><volume>61</volume><fpage>113</fpage><lpage>122</lpage><year>2012</year></element-citation></ref>
<ref id="b24-or-32-02-0559"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XJ</given-names></name><name><surname>Peng</surname><given-names>LX</given-names></name><name><surname>Shao</surname><given-names>JY</given-names></name><etal/></person-group><article-title>As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>1302</fpage><lpage>1309</lpage><year>2012</year></element-citation></ref>
<ref id="b25-or-32-02-0559"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horikawa</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma</article-title><source>Cancer Res</source><volume>67</volume><fpage>1970</fpage><lpage>1978</lpage><year>2007</year></element-citation></ref>
<ref id="b26-or-32-02-0559"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Transforming growth factor-&#x003B2;1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways</article-title><source>Mol Biol Rep</source><volume>39</volume><fpage>3549</fpage><lpage>3556</lpage><year>2012</year></element-citation></ref>
<ref id="b27-or-32-02-0559"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Seo</surname><given-names>JE</given-names></name><name><surname>Oh</surname><given-names>SC</given-names></name><name><surname>Yoo</surname><given-names>YA</given-names></name></person-group><article-title>BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway</article-title><source>Exp Cell Res</source><volume>316</volume><fpage>24</fpage><lpage>37</lpage><year>2010</year></element-citation></ref>
<ref id="b28-or-32-02-0559"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Induction of an EMT-like transformation and MET in vitro</article-title><source>J Transl Med</source><volume>11</volume><fpage>164</fpage><year>2013</year></element-citation></ref>
<ref id="b29-or-32-02-0559"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name></person-group><article-title>Complex networks orchestrate epithelial-mesenchymal transitions</article-title><source>Nat Rev Mol Cell Biol</source><volume>7</volume><fpage>131</fpage><lpage>142</lpage><year>2006</year></element-citation></ref>
<ref id="b30-or-32-02-0559"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battula</surname><given-names>VL</given-names></name><name><surname>Evans</surname><given-names>KW</given-names></name><name><surname>Hollier</surname><given-names>BG</given-names></name><etal/></person-group><article-title>Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells</article-title><source>Stem Cells</source><volume>28</volume><fpage>1435</fpage><lpage>1445</lpage><year>2010</year></element-citation></ref>
<ref id="b31-or-32-02-0559"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>QL</given-names></name><name><surname>Hu</surname><given-names>LJ</given-names></name><name><surname>Cao</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma</article-title><source>PLoS Pathog</source><volume>6</volume><fpage>e1000940</fpage><year>2010</year></element-citation></ref>
<ref id="b32-or-32-02-0559"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>BL</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Dong</surname><given-names>MM</given-names></name></person-group><article-title>Cancer stem-like side population cells in the human nasopharyngeal carcinoma cell line CNE-2 possess epithelial mesenchymal transition properties in association with metastasis</article-title><source>Oncol Rep</source><volume>28</volume><fpage>241</fpage><lpage>247</lpage><year>2012</year></element-citation></ref>
<ref id="b33-or-32-02-0559"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Shen</surname><given-names>YA</given-names></name><name><surname>Hung</surname><given-names>PH</given-names></name><name><surname>Yu</surname><given-names>YB</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name></person-group><article-title>Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines</article-title><source>BMC Complement Altern Med</source><volume>12</volume><fpage>201</fpage><year>2012</year></element-citation></ref>
<ref id="b34-or-32-02-0559"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jazirehi</surname><given-names>AR</given-names></name><name><surname>Wenn</surname><given-names>PB</given-names></name><name><surname>Damavand</surname><given-names>M</given-names></name></person-group><article-title>Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy</article-title><source>Am J Cancer Res</source><volume>2</volume><fpage>178</fpage><lpage>191</lpage><year>2012</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-32-02-0559" position="float">
<label>Figure 1</label>
<caption>
<p>Immunohistochemical analysis of p-Akt (Ser473) and EMT marker expression in clinical samples from nasopharyngitis and nasopharyngeal carcinoma (NPC). Non-immune IgG was used as a negative control. E-cadherin expression in epithelial cells of nasopharyngitis samples was located in membranes while it was mainly located in the cytoplasm of metastatic NPC cells. Spindle and fibroblast-like tumor cells in NPC metastatic samples showed intense staining for vimentin and &#x003B1;-SMA. Left, nasopharyngitis; middle, NPC primary lesions; right, NPC metastatic lesions. Magnification, &#x000D7;200. Scale bar, 100 &#x003BC;M.</p></caption>
<graphic xlink:href="OR-32-02-0559-g00.gif"/></fig>
<fig id="f2-or-32-02-0559" position="float">
<label>Figure 2</label>
<caption>
<p>Activation of PI3K/Akt signaling and expression of E-cadherin, vimentin and &#x003B1;-SMA in CNE2Z cells. (A) p-Akt (Ser473) and total Akt expression in CNE2Z cells treated with LY294002 or vehicle (DMSO) were examined by western blotting. (B) Expression of E-cadherin, vimentin and &#x003B1;-SMA in CNE2Z cells treated with LY294002 or vehicle (DMSO) were examined by western blotting. (C) qPCR analysis of LY294002-treated CNE2Z cells. &#x003B2;-actin served as the loading control. <sup>*,&#x025B3;,#</sup>P&lt;0.05 vs. DMSO; <sup>**,&#x025B3;&#x025B3;,##</sup>P&lt;0.01 vs. DMSO.</p></caption>
<graphic xlink:href="OR-32-02-0559-g01.gif"/></fig>
<fig id="f3-or-32-02-0559" position="float">
<label>Figure 3</label>
<caption>
<p>Treatment of CNE2Z cells with LY294002 suppresses cell migration and invasion. (A) Representative images of cell migration and invasion. (B) Numbers of migrating and invading CNE2Z cells. <sup>**, ##</sup>P&lt;0.01 vs. DMSO. Scale bar, 100 &#x003BC;M.</p></caption>
<graphic xlink:href="OR-32-02-0559-g02.gif"/></fig>
<fig id="f4-or-32-02-0559" position="float">
<label>Figure 4</label>
<caption>
<p>Expression of E-cadherin, vimentin and &#x003B1;-SMA in xenografts of CNE2Z cell-bearing mice. Western blot analysis of EMT marker expression, with &#x003B2;-actin serving as loading control.</p></caption>
<graphic xlink:href="OR-32-02-0559-g03.gif"/></fig>
<fig id="f5-or-32-02-0559" position="float">
<label>Figure 5</label>
<caption>
<p>Immunohistochemical analysis of E-cadherin, vimentin and &#x003B1;-SMA expression in xenografts of CNE2Z cell-bearing mice. Primary tumor masses were used for immunohistochemical analysis of EMT marker expression. Left, DMSO; middle, 10 mg/kg LY294002; right, 75 mg/kg LY294002. Magnification, &#x000D7;200. Scale bar, 100 &#x003BC;M.</p></caption>
<graphic xlink:href="OR-32-02-0559-g04.gif"/></fig>
<fig id="f6-or-32-02-0559" position="float">
<label>Figure 6</label>
<caption>
<p>Pulmonary metastasis of CNE2Z cell-bearing mice. (A) Pulmonary metastatic lesions stained with hematoxylin and eosin. Magnification, &#x000D7;200. Scale bar, 100 &#x003BC;M. (B) Total pulmonary tumor metastatic lesions in CEN2Z cell-bearing mice. <sup>***</sup>P&lt;0.001 vs. other groups.</p></caption>
<graphic xlink:href="OR-32-02-0559-g05.gif"/></fig>
<table-wrap id="tI-or-32-02-0559" position="float">
<label>Table I</label>
<caption>
<p>Expression of p-Akt (Ser473), membrane E-cadherin, cytosol vimentin and <xref rid="tfn1-or-32-02-0559" ref-type="table-fn">&#x003B1;</xref>-SMA in clinical nasopharyngitis and NPC samples.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left">Conditions</th>
<th valign="bottom" align="center">n</th>
<th valign="bottom" align="center">p-Akt (Ser473) + (&#x00025;)</th>
<th valign="bottom" align="center">P-value</th>
<th valign="bottom" align="center">E-cadherin + (&#x00025;)</th>
<th valign="bottom" align="center">P-value</th>
<th valign="bottom" align="center">Vimentin + (&#x00025;)</th>
<th valign="bottom" align="center">P-value</th>
<th valign="bottom" align="center"><xref rid="tfn1-or-32-02-0559" ref-type="table-fn">&#x003B1;</xref>-SMA + (&#x00025;)</th>
<th valign="bottom" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Tissue type</td>
<td valign="top" align="right"/>
<td valign="top" align="right"/>
<td valign="top" align="left">&lt;0.001</td>
<td valign="top" align="left"/>
<td valign="top" align="center">&lt;0.05</td>
<td valign="top" align="center"/>
<td valign="top" align="left">&lt;0.001</td>
<td valign="top" align="center"/>
<td valign="top" align="center">&lt;0.01</td></tr>
<tr>
<td valign="top" align="left">&#x02003;NPC</td>
<td valign="top" align="right">130</td>
<td valign="top" align="right">99 (76.2)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">98 (75.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">53 (40.8)</td>
<td valign="top" align="left"/>
<td valign="top" align="center">48 (36.9)</td>
<td valign="top" align="center"/></tr>
<tr>
<td valign="top" align="left">&#x02003;Nasopharyngitis</td>
<td valign="top" align="right">20</td>
<td valign="top" align="right">5 (25.0)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">20 (100.0)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">0</td>
<td valign="top" align="left"/>
<td valign="top" align="center">0</td>
<td valign="top" align="center"/></tr>
<tr>
<td valign="top" align="left">Metastasis</td>
<td valign="top" align="right"/>
<td valign="top" align="right"/>
<td valign="top" align="left">&lt;0.01</td>
<td valign="top" align="left"/>
<td valign="top" align="center">&lt;0.01</td>
<td valign="top" align="center"/>
<td valign="top" align="left">&lt;0.001</td>
<td valign="top" align="center"/>
<td valign="top" align="center">&lt;0.05</td></tr>
<tr>
<td valign="top" align="left">&#x02003;With</td>
<td valign="top" align="right">53</td>
<td valign="top" align="right">47 (88.7)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">33 (62.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">32 (60.4)</td>
<td valign="top" align="left"/>
<td valign="top" align="center">25 (47.2)</td>
<td valign="top" align="center"/></tr>
<tr>
<td valign="top" align="left">&#x02003;Without</td>
<td valign="top" align="right">77</td>
<td valign="top" align="right">52 (67.5)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">65 (84.4)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">21 (27.3)</td>
<td valign="top" align="left"/>
<td valign="top" align="center">23 (29.9)</td>
<td valign="top" align="center"/></tr>
<tr>
<td valign="top" align="left">Matched lesion</td>
<td valign="top" align="right"/>
<td valign="top" align="right"/>
<td valign="top" align="left">&lt;0.05</td>
<td valign="top" align="left"/>
<td valign="top" align="center">&lt;0.05</td>
<td valign="top" align="center"/>
<td valign="top" align="left">&lt;0.05</td>
<td valign="top" align="center"/>
<td valign="top" align="center">&gt;0.05</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Primary</td>
<td valign="top" align="right">23</td>
<td valign="top" align="right">10 (43.5)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">18 (78.3)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">15 (65.2)</td>
<td valign="top" align="left"/>
<td valign="top" align="center">7 (30.4)</td>
<td valign="top" align="center"/></tr>
<tr>
<td valign="top" align="left">&#x02003;Secondary</td>
<td valign="top" align="right">23</td>
<td valign="top" align="right">18 (78.3)</td>
<td valign="top" align="left"/>
<td valign="top" align="left">11 (47.8)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">7 (30.4)</td>
<td valign="top" align="left"/>
<td valign="top" align="center">13 (56.5)</td>
<td valign="top" align="center"/></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-or-32-02-0559">
<p>&#x003B1;-SMA, &#x003B1; smooth muscle actin; NPC, nasopharyngeal carcinoma.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
